Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

International Journal of Clinical Oncology volume 17, pages1–29(2012)Cite this article

Abstract

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15

Notes

  1. 1.

    In polypectomy, a snare is placed on the stalk of the lesion, and the lesion is electrocauterized using a high-frequency current. This method is mainly used for protruding lesions.

  2. 2.

    In EMR, the lesion is elevated through the local injection of a liquid such as physiological saline into the submucosa, and the lesion is electrocauterized just as in polypectomy. This method comprises the snare method [2] and EMR using a cap (EMRC). It is mainly used for superficial tumors and large sessile lesions.

  3. 3.

    In ESD, the lesion is elevated through the local injection of a liquid such as sodium hyaluronate solution into the submucosa of the perilesional area; then, circumferential incision of the mucosa surrounding the lesion and dissection of the submucosa are performed with a special knife [3]. ESD is mainly indicated for large tumors that cannot be resected by EMR.

  4. 4.

    FOLFOX is infusional 5-FU + LV + L-OHP.

  5. 5.

    CapeOX is capecitabine + L-OHP.

  6. 6.

    FOLFIRI is infusional 5-FU + LV + CPT-11.

References

  1. 1.

    Japanese Society for Cancer of the Colon and Rectum (2010) JSCCR guidelines 2010 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo

  2. 2.

    Kudo S (1993) Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 25:455–461

    Google Scholar 

  3. 3.

    Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection (ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection (EMR). J Gastroenterol 43:641–651

    Google Scholar 

  4. 4.

    Japanese Society for Cancer of the Colon and Rectum (2010) Multi-Institutional Registry of Large Bowel Cancer in Japan. Cases treated in 1995–1998 [vols. 17 (1999), 18 (2000), 21 (2001), 24 (2003)]. Japanese Society for Cancer of the Colon and Rectum, Tokyo

  5. 5.

    Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335–346

    CAS  PubMed  Google Scholar 

  8. 8.

    Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 44:915–919

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663–1672

    Article  PubMed  Google Scholar 

  10. 10.

    Japanese Society for Cancer of the Colon and Rectum (1998) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 6th edn. Kanehara & Co., Ltd., Tokyo

  11. 11.

    Mentges B, Buess G, Schafer D et al (1996) Local therapy of rectal tumors. Dis Colon Rectum 39:886–892

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086–1093

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–76

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Lambert LA, Colacchio TA, Barth RJ Jr (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135:473–479

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090–1096

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–218

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    National Institute of Health Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450

    Google Scholar 

  19. 19.

    Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408

    Article  PubMed  Google Scholar 

  20. 20.

    Van Cutsem E, Oliveira J, ESMO Guidelines Working Group (2008) Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19(Suppl 2):ii29–ii30

    Google Scholar 

  21. 21.

    André T, Boni C, Mounedji-Boudiaf L et al, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Google Scholar 

  22. 22.

    Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116

    Article  PubMed  Google Scholar 

  24. 24.

    Wolmark N, Wieand S, Kuebler PJ et al (2008) A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 26 (Abstr LBA4005)

  25. 25.

    Haller D, Tabernero J, Maroun J et al (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). In: Proc ECCO 15–34th ESMO Congr, Berlin, Germany, 20–24 Sept 2009, Abstr 5LBA

  26. 26.

    Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678

    Article  PubMed  Google Scholar 

  27. 27.

    Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752–755

    Article  CAS  Google Scholar 

  28. 28.

    Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321:531–535

    Article  CAS  Google Scholar 

  29. 29.

    Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  31. 31.

    Goldberg R, Sargent D, Morton R et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22:229–237

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Fuchs CS, Marshall J, Barrueco J et al (2008) Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26:689–690

    Article  PubMed  Google Scholar 

  38. 38.

    Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  39. 39.

    Siena S, Cassidy J, Tabernero J et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 283

  40. 40.

    Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  41. 41.

    Kohne C, Mineur L, Greil R et al (2010) Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 414

  42. 42.

    Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565

    CAS  PubMed  Google Scholar 

  43. 43.

    Hurwitz H, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508

    Article  CAS  PubMed  Google Scholar 

  44. 44.

    Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Google Scholar 

  45. 45.

    Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319

    Article  CAS  PubMed  Google Scholar 

  47. 47.

    Peeters M, Price TJ, Hotko YS et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 282

  48. 48.

    Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069

    Article  CAS  PubMed  Google Scholar 

  49. 49.

    Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  50. 50.

    Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726

    Article  CAS  PubMed  Google Scholar 

  51. 51.

    Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  52. 52.

    Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048

    Article  CAS  PubMed  Google Scholar 

  53. 53.

    Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  54. 54.

    Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  Google Scholar 

  55. 55.

    Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  CAS  PubMed  Google Scholar 

  56. 56.

    Skibber JM, Hoff PM, Minsky BD et al (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1271–1318

    Google Scholar 

  57. 57.

    Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987

    Google Scholar 

  58. 58.

    Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284:1008–1015

    Article  CAS  Google Scholar 

  59. 59.

    Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291–1304

    Google Scholar 

  60. 60.

    Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646

    Article  CAS  PubMed  Google Scholar 

  61. 61.

    Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701

    Article  PubMed  Google Scholar 

  62. 62.

    Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858

    Article  PubMed  Google Scholar 

  63. 63.

    Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206

    Article  CAS  PubMed  Google Scholar 

  64. 64.

    Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial. J Clin Oncol 17:2396–2402

    CAS  PubMed  Google Scholar 

  65. 65.

    Bosset JF, Collette L, Calais G et al, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123

    Google Scholar 

  66. 66.

    Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625

    Article  PubMed  Google Scholar 

  67. 67.

    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223

    Article  CAS  PubMed  Google Scholar 

  68. 68.

    Sauer R, Becker H, Hohenberger W, German Rectal Cancer Study Group et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Google Scholar 

  69. 69.

    WHO (1990) Cancer pain relief and palliative care (WHO Tech Rep Ser 804). WHO, Geneva, pp 21–22

  70. 70.

    Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 324:813–816

    Article  Google Scholar 

  71. 71.

    Figueredo A, Rumble RB, Maroun J et al (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 6:26

    Article  Google Scholar 

  72. 72.

    Renehan AG, Egger M, Saunders MP et al (2005) Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 92:430–433

    CAS  PubMed  Google Scholar 

  73. 73.

    Jeffery M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 24:CD002200

    Google Scholar 

  74. 74.

    Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799

    Article  PubMed  Google Scholar 

  75. 75.

    Bruinvels D, Stiggelbout A, Kievit J et al (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174–182

    Article  CAS  PubMed  Google Scholar 

  76. 76.

    Fleischer D, Goldberg S, Browning T et al (1989) Detection and surveillance of colorectal cancer. JAMA 261:580–585

    Article  CAS  PubMed  Google Scholar 

  77. 77.

    Green RJ, Metlay JP, Propert K et al (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 136:261–269

    CAS  PubMed  Google Scholar 

  78. 78.

    Berman J, Cheung R, Weiberg D (2000) Surveillance after colorectal cancer resection. Lancet 355:395–399

    Article  CAS  PubMed  Google Scholar 

  79. 79.

    Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394

    Article  PubMed  Google Scholar 

  80. 80.

    Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534–543

    Article  PubMed  Google Scholar 

  81. 81.

    Tanaka S, Haruma K, Oh-e H et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783–788

    CAS  PubMed  Google Scholar 

  82. 82.

    Japanese Society for Cancer of the Colon and Rectum (1980) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 2nd edn. Kanehara & Co., Ltd., Tokyo

  83. 83.

    Japanese Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 5th edn. Kanehara & Co., Ltd., Tokyo

  84. 84.

    Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR guidelines 2005 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo

  85. 85.

    Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717–723

    Article  CAS  PubMed  Google Scholar 

  86. 86.

    Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379

    Article  PubMed  Google Scholar 

  87. 87.

    Lièvre A, Bachet JB, Corre DL et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Google Scholar 

  88. 88.

    Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237

    Article  CAS  PubMed  Google Scholar 

  89. 89.

    de Reyniès A, Boige V, Milano G et al (2007) KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26:2228–2230

    Google Scholar 

  90. 90.

    Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166–1169

    Google Scholar 

  91. 91.

    Wierzbicki R, Jonker DJ, Moore MJ et al (2009) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 23:1803–1810

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan

    Toshiaki Watanabe

  2. Department of Surgery 2, Tokyo Women’s Medical University, Tokyo, Japan

    Michio Itabashi

  3. Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    Yasuhiro Shimada & Tetsuya Hamaguchi

  4. Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan

    Shinji Tanaka

  5. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

    Yoshinori Ito

  6. Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

    Yoichi Ajioka

  7. Division of Gastroenterology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

    Ichinosuke Hyodo

  8. Department of Endoscopy, Cancer Institute Ariake Hospital, Tokyo, Japan

    Masahiro Igarashi

  9. Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Hideyuki Ishida

  10. Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan

    Megumi Ishiguro & Kenichi Sugihara

  11. Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan

    Yukihide Kanemitsu

  12. Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Norihiro Kokudo

  13. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

    Kei Muro

  14. Pathology Division, Research Center for Innovative Oncology, National Cancer Centre Hospital East, Chiba, Japan

    Atsushi Ochiai

  15. Radiation Oncology Department, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

    Masahiko Oguchi

  16. Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan

    Yasuo Ohkura

  17. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan

    Yutaka Saito

  18. Department of Surgery, Kyoto University, Kyoto, Japan

    Yoshiharu Sakai

  19. Department of Surgery, National Defense Medical College, Saitama, Japan

    Hideki Ueno

  20. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan

    Takayuki Yoshino

  21. Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine, Tochigi, Japan

    Takahiro Fujimori

  22. Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, Sendai, Japan

    Nobuo Koinuma

  23. Department of Surgery, Cancer Center, Aomori Prefectural Central Hospital, Aomori, Japan

    Takayuki Morita

  24. Department of Surgery, Japanese Red Cross Kanazawa Hospital, Ishikawa, Japan

    Genichi Nishimura

  25. Department of Internal Medicine and Medical Oncology, Misawa City Hospital, Misawa, Japan

    Yuh Sakata

  26. Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Keiichi Takahashi

  27. Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan

    Hiroya Takiuchi

  28. Division of Gastrointestinal Endoscopy, Kurume University School of Medicine, Fukuoka, Japan

    Osamu Tsuruta

  29. Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan

    Toshiharu Yamaguchi

  30. Department of Hemodialysis and Surgery, Chemotherapy Research Institute, International University of Health and Welfare, Ichikawa, Japan

    Masahiro Yoshida

  31. Library, Toho University Medical Center Sakura Hospital, Chiba, Japan

    Naohiko Yamaguchi

  32. Department of Surgery, Tochigi Cancer Center, Utsunomiya, Japan

    Kenjiro Kotake

Authors
  1. Toshiaki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michio Itabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoichi Ajioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuya Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ichinosuke Hyodo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Igarashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideyuki Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Megumi Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yukihide Kanemitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Norihiro Kokudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kei Muro
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Atsushi Ochiai
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Masahiko Oguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yasuo Ohkura
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yutaka Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshiharu Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Hideki Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Takayuki Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Takahiro Fujimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Nobuo Koinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Takayuki Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Genichi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Yuh Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Keiichi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Hiroya Takiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Osamu Tsuruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Toshiharu Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Masahiro Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Naohiko Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Kenjiro Kotake
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Kenichi Sugihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Japanese Society for Cancer of the Colon and Rectum

Corresponding author

Correspondence to Toshiaki Watanabe.

Additional information

This article was originally appeared in Japanese as Daicho gan chiryo gaidorain · Ishiyo 2010 nen ban (JSCCR Guidelines 2010 for the Treatment of Colorectal Cancer), published by Kanehara, Tokyo, 2010.

About this article

Cite this article

Watanabe, T., Itabashi, M., Shimada, Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17, 1–29 (2012). https://doi.org/10.1007/s10147-011-0315-2

Download citation

Keywords

  • Colorectal cancer
  • Guideline
  • Treatment
  • Surgery
  • Chemotherapy
  • Endoscopy
  • Radiotherapy
  • Palliative care
  • Surveillance